AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

morningstar.com
·

How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks

GLP-1 drugs like Ozempic and Mounjaro are gaining attention as blockbuster drugs face patent cliffs. These drugs, initially for diabetes, now show significant weight loss, positioning them as next-gen treatments. Competition is fierce, with Novo Nordisk and Eli Lilly leading, but other companies like Amgen, Roche, Pfizer, and AstraZeneca are entering the market. Expanding the conditions these drugs treat could influence insurance coverage. The snack industry may need to innovate as GLP-1 drugs reduce processed food consumption. The patent cliff threatens big pharma, but Medicare negotiations and biologic drugs offer strategies. Innovations like pill-form obesity drugs and mRNA cancer treatments are on the horizon. Oncology and immunology remain dominant, but obesity is emerging as a significant driver. Stock picks include Roche, mRNA companies, and Pfizer.
bnnbloomberg.ca
·

Sanofi Blockbuster Drug Wins Clearance in US for Lung Disease

Sanofi's Dupixent approved by US FDA for COPD, following EU approval, marking a decade's first new treatment approach for the disease. The drug, co-developed with Regeneron, is expected to generate €21 billion annually by 2030 before facing patent expirations.
biopharmadive.com
·

FDA, after delay, clears Regeneron and Sanofi drug for COPD

FDA approves Dupixent for COPD, making it the first biologic medicine for the condition in the U.S. This expansion is expected to boost sales, which reached almost $12 billion globally last year. Dupixent targets Type 2 inflammation in a subset of COPD patients, showing reduced exacerbations and improved lung function in trials. European regulators approved Dupixent for COPD in July, but U.S. approval required additional efficacy data. The approval comes as Regeneron faces market value loss due to a court case, increasing pressure on its pipeline.

AstraZeneca's Tagrisso gains FDA approval for stage III NSCLC

FDA approves AstraZeneca's Tagrisso for unresectable stage III EGFR-mutated NSCLC, based on LAURA Phase III trial showing 84% reduction in disease progression or death compared to placebo, with median progression-free survival of 39.1 months.
pharmexec.com
·

FDA Approves Tagrisso for Unresectable Stage III Epidermal Growth Factor Receptor

FDA approves AstraZeneca's Tagrisso for unresectable stage III EGFR-mutated NSCLC after platinum-based chemoradiation. Tagrisso reduced disease progression risk by 84% in LAURA trial, with median PFS of 39.1 months vs 5.6 months for placebo. Safety profile consistent, but includes serious AEs. Lung cancer affects 2.4 million globally, with 10-15% in US/Europe and 30-40% in Asia having EGFRm NSCLC.
biospace.com
·

TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR ...

AstraZeneca's TAGRISSO® (osimertinib) approved in the US for treating unresectable, Stage III EGFRm NSCLC patients who haven't progressed post-CRT. TAGRISSO reduced disease progression risk by 84% in LAURA Phase III trial, extending median PFS to 39.1 months.
drugs.com
·

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

FDA approves AstraZeneca's Tagrisso for unresectable, Stage III EGFR-mutated lung cancer, based on LAURA Phase III trial results showing 84% reduction in disease progression risk.
globenewswire.com
·

Global Bispecific Antibodies Clinical Trials Market Size

Bispecific antibodies market highlights include >30 development platforms, >USD 8B market size in 2023, and >800 clinical trials. Key approved antibodies like Blincyto and Hemlibra have seen significant sales. The market is driven by innovations in immuno-oncology, with ongoing trials by major pharma companies and research institutions globally.
empr.com
·

Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC

FDA approves Tagrisso (osimertinib) for stage III unresectable NSCLC with EGFR mutations not progressed post-CRT. LAURA trial showed osimertinib reduced progression risk by 84% vs placebo, with median PFS of 39.1 months vs 5.6 months. Adverse reactions include lymphopenia, leukopenia, and COVID-19.
© Copyright 2024. All Rights Reserved by MedPath